ALK-positive plasmablastic B-cell lymphoma with the clathrin-ALK gene rearrangement.
Isimbaldi
Giuseppe
G
Bandiera
Laura
L
d'Amore
Emanuele S G
ES
Conter
Valentino
V
Milani
Marina
M
Mussolin
Lara
L
Rosolen
Angelo
A
D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001215:Asparaginase / Q000008:administration & dosage; D002648:Child; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D002889:Chromosomes, Human, Pair 2 / Q000235:genetics; D002966:Clathrin / Q000235:genetics*; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D015321:Gene Rearrangement / Q000235:genetics*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D011241:Prednisone / Q000008:administration & dosage; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D020794:Receptor Protein-Tyrosine Kinases; D014178:Translocation, Genetic / Q000235:genetics; D014750:Vincristine / Q000008:administration & dosage
D002966:Clathrin; D015514:Oncogene Proteins, Fusion; D014750:Vincristine; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases; D001215:Asparaginase; D011241:Prednisone; D003630:Daunorubicin